Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C77H109N21O19S |
| Molecular Weight | 1664.884 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 12 / 12 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC4=CNC5=CC=CC=C45)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N6CCC[C@H]6C(=O)N[C@@H](C(C)C)C(N)=O
InChI
InChIKey=WHNFPRLDDSXQCL-UAZQEYIDSA-N
InChI=1S/C77H109N21O19S/c1-42(2)64(65(79)106)97-75(116)61-20-13-30-98(61)76(117)54(18-10-11-28-78)88-62(103)38-85-66(107)57(34-46-36-84-50-17-9-8-16-49(46)50)94-67(108)51(19-12-29-83-77(80)81)89-70(111)55(32-44-14-6-5-7-15-44)92-72(113)58(35-47-37-82-41-86-47)95-68(109)52(25-26-63(104)105)90-69(110)53(27-31-118-4)91-74(115)60(40-100)96-71(112)56(33-45-21-23-48(102)24-22-45)93-73(114)59(39-99)87-43(3)101/h5-9,14-17,21-24,36-37,41-42,51-61,64,84,99-100,102H,10-13,18-20,25-35,38-40,78H2,1-4H3,(H2,79,106)(H,82,86)(H,85,107)(H,87,101)(H,88,103)(H,89,111)(H,90,110)(H,91,115)(H,92,113)(H,93,114)(H,94,108)(H,95,109)(H,96,112)(H,97,116)(H,104,105)(H4,80,81,83)/t51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,64-/m0/s1
| Molecular Formula | C77H109N21O19S |
| Molecular Weight | 1664.884 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 12 / 12 |
| E/Z Centers | 6 |
| Optical Activity | UNSPECIFIED |
alpha-MELANOTROPIN (also known as an alpha-melanocyte-stimulating hormone or alpha MSH) is an endogenous melanocortin 1-receptor agonist, which exclusively expressed in cells of the melanocytic lineage. alpha-MELANOTROPIN possesses anti-inflammatory properties and antagonizes proinflammatory mediators, including TNF-alpha, IL-6 and NO, and induces anti-inflammatory cytokine IL-10. alpha-MELANOTROPIN was studied in phase I clinical trial in patients with acute renal failure. In addition, this compound was assigned of orphan designation for the treatment of chronic beryllium disease.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Immunoreactive alpha-melanotropin as an autocrine effector in human melanoma cells. | 1997 Mar 15 |
|
| Discovery of novel melanocortin4 receptor selective MSH analogues. | 1998 May |
|
| The stimulatory effect of alpha-melanotropin on progesterone release from rat granulosa cells is inhibited by interleukin-1beta and by tumour necrosis factor-alpha. | 2004 Oct |
Sample Use Guides
Patients are infused with alpha-melanocyte stimulating hormone (alpha-MSH) or placebo over 5 minutes. A cohort of 5 patients is infused at each dose level of alpha-MSH until the minimum effective dose (MED) and the maximum tolerated dose (MTD) are determined.
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:12:06 GMT 2023
by
admin
on
Fri Dec 15 16:12:06 GMT 2023
|
| Record UNII |
OVF025LA77
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
308910
Created by
admin on Fri Dec 15 16:12:06 GMT 2023 , Edited by admin on Fri Dec 15 16:12:06 GMT 2023
|
||
|
FDA ORPHAN DRUG |
106497
Created by
admin on Fri Dec 15 16:12:06 GMT 2023 , Edited by admin on Fri Dec 15 16:12:06 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
4214
Created by
admin on Fri Dec 15 16:12:06 GMT 2023 , Edited by admin on Fri Dec 15 16:12:06 GMT 2023
|
PRIMARY | |||
|
SUB30314
Created by
admin on Fri Dec 15 16:12:06 GMT 2023 , Edited by admin on Fri Dec 15 16:12:06 GMT 2023
|
PRIMARY | |||
|
5941
Created by
admin on Fri Dec 15 16:12:06 GMT 2023 , Edited by admin on Fri Dec 15 16:12:06 GMT 2023
|
PRIMARY | |||
|
581-05-5
Created by
admin on Fri Dec 15 16:12:06 GMT 2023 , Edited by admin on Fri Dec 15 16:12:06 GMT 2023
|
PRIMARY | |||
|
C174814
Created by
admin on Fri Dec 15 16:12:06 GMT 2023 , Edited by admin on Fri Dec 15 16:12:06 GMT 2023
|
PRIMARY | |||
|
16132144
Created by
admin on Fri Dec 15 16:12:06 GMT 2023 , Edited by admin on Fri Dec 15 16:12:06 GMT 2023
|
PRIMARY | |||
|
D000521
Created by
admin on Fri Dec 15 16:12:06 GMT 2023 , Edited by admin on Fri Dec 15 16:12:06 GMT 2023
|
PRIMARY | |||
|
m7651
Created by
admin on Fri Dec 15 16:12:06 GMT 2023 , Edited by admin on Fri Dec 15 16:12:06 GMT 2023
|
PRIMARY | Merck Index | ||
|
OVF025LA77
Created by
admin on Fri Dec 15 16:12:06 GMT 2023 , Edited by admin on Fri Dec 15 16:12:06 GMT 2023
|
PRIMARY | |||
|
9002-79-3
Created by
admin on Fri Dec 15 16:12:06 GMT 2023 , Edited by admin on Fri Dec 15 16:12:06 GMT 2023
|
NO STRUCTURE GIVEN | |||
|
MELANOCYTE-STIMULATING_HORMONE
Created by
admin on Fri Dec 15 16:12:06 GMT 2023 , Edited by admin on Fri Dec 15 16:12:06 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
DERIVATIVE -> PARENT |
|
||
|
|
DERIVATIVE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
